POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24h (3.3.2021, 10:18am CET, WHO):   U.S. 50,776    India 14,989    Brazil 35,742    Russia 10,565    The United Kingdom 5,455    France 4,703    Spain 1,159    Italy 13,106    Turkey 9,891    Germany 3,943    Columbia 3,570    Argentina 6,653    Mexico 2,343    Poland 7,936    Iran 8,495    Ukraine 5,336    Indonesia 5,712    Peru 3,134    Czechia 12,191    The Netherlands 3,826    Canada 3,530    Chile 2,742    Romania 2,096    Israel 3,123    Iraq 4,690    Pakistan 1,163    Philippines 2,061    Serbia 3,469    Jordan 5,124    United Arab Emirates 2,721    Lebanon 3,098    Slovakia 2,077    Malaysia 1,555    Bulgaria 2,588    Palestine 2,412    Kuwait 1,341    Greece 1,170    Estonia 1,111    Botswana 2,357    China 23    Singapore 8    New Zealand 2    Australia 8    South Korea 444   

EU rushes to authorize Remdesivir as U.S. hoards it

Christian Fernsby |
The European Commission on Friday rushed to announce it has given the green light to anti-viral drug Remdesivir for treatment of coronavirus, making it the first drug authorized at the European Union (EU) level for the purpose.

Article continues below



Topics: REMDESIVIR    U.S.   

EU Commissioner for Health and Food Safety Stella Kyriakides said the EU has expedited the authorization, approving the drug, made by American biopharmaceutical company Gilead Sciences, in an exceptionally short timeframe.

"We will leave no stone unturned in our efforts to secure efficient treatments or vaccine against the coronavirus," said Kyriakides in a statement.

The question now is whether there are enough doses to be left at the disposal of the EU in the near future, as news broke this week that the United States has locked down all the production for July and 90 percent of it for August and September.

Gino Martini, chief scientist of the Royal Pharmaceutical Society of Great Britain, said the U.S. action will put clinical supply chains under strain, and it will be down to Gilead to boost production in order to satisfy the demand.

He noted that Remdesivir is still classed as an investigational drug, and its use for COVID-19 in the United States is only permitted in emergency use.

"Scaling up medicines to a production level is not a trivial matter and is controlled by regulatory and quality control standards and so takes time," he said.

The professor said he would expect Remdesivir to "become available simultaneously across the world" if the evidence continues to support the use of Remdesivir to treat coronavirus.

A spokesman for the European Commission told a press conference on Thursday that Brussels heard of the U.S. move from media reports, meaning Washington didn't bother to inform its allies beforehand.

The U.S. move seemed more annoying to European experts.

Ohid Yaqub, a senior lecturer at the Science Policy Research Unit, University of Sussex in England, said the buying-up of Remdesivir is disappointing "not necessarily because of the shortages it implies for other countries, but because it so clearly signals an unwillingness to cooperate with other countries."

Karl Lauterbach, an epidemiologist and health expert of Social Democratic Party of Germany, called it an "unfriendly" action. "If we approached the vaccine this way later, we would certainly all have big problems," Lauterbach told German broadcasting Deutschlandfunk.


What to read next

Japan approves remdesivir for coronavirus treatment
EU agency recommends first remdesivir coronavirus treatment
Coronavirus: 79 year old Italian man successfully treated with experimental drug